RAPath SG
Singapore Medical Device Regulatory Reference
RAPath SG is a plain English reference for Singapore medical device regulation under the Health Products Act (Cap. 122D) and the Health Products (Medical Devices) Regulations 2010. It is designed for regulatory affairs professionals, manufacturers, importers, wholesalers, registrants, and consultants navigating the Health Sciences Authority (HSA) framework.
This site does not replace official HSA sources. Every page links back to the authoritative legislative text or official HSA guidance. Think of RAPath SG as a structured, searchable index that helps you find what you need — then points you to the official source to verify it.
Who this site is for
Regulatory affairs professionals and consultants — a well-structured reference for requirements you navigate daily, with every claim linked to its legislative or regulatory source.
Manufacturers (Singapore and overseas) — understand what the Singapore regulatory framework requires of you, including product registration and dealer's licensing obligations, and how the framework relates to systems you may already know (TGA, FDA, CE, Health Canada).
Importers and wholesalers — understand when and why you need a dealer's licence, what Good Distribution Practice (GDP) means in practice, and how your obligations differ from the product registrant's obligations.
Registrants — understand the full registration lifecycle from classification and grouping through to evaluation route selection, SHARE submission, and post-market maintenance.
Anyone new to Singapore medical device regulation — start with Start Here for a guided introduction to the framework.
What makes Singapore distinctive
Singapore's regulatory framework has several features that frequently surprise practitioners coming from other jurisdictions:
The dual obligation model. Unlike most other frameworks, Singapore separates product registration (the device's entry on the Singapore Medical Device Register) from dealer's licensing (the company's authorisation to manufacture, import, or wholesale). Both are mandatory. A registered device cannot be lawfully supplied without a licensed dealer, and a licensed dealer cannot supply an unregistered device. The Dealer's Licence section covers this in full.
Class A devices are exempt from registration — but not from notification. Class A (lowest-risk) devices do not require product registration. However, companies that manufacture or import Class A devices must still submit a product notification via the SHARE portal. Many companies overlook this. See Class A — Exemption and Notification.
Registration route depends heavily on overseas approvals. Whether a Class B, C, or D device goes through Full, Abridged, Expedited, or Immediate evaluation depends on the number and type of approvals already held from HSA's five recognised overseas reference agencies (TGA, EU NB, Health Canada, MHLW, FDA). This is central to Singapore market entry strategy. See Evaluation Routes.
Device grouping is a formal pre-submission decision. Singapore has specific rules for grouping devices into a single registration application (Family, System, Group, Single, and several IVD variants). Grouping decisions affect fees, timelines, and ongoing change notification obligations. See Device Grouping.
How to use this site
The site is structured around the regulatory lifecycle of a medical device in Singapore:
| Section | What it covers |
|---|---|
| Start Here | Definitions, regulatory framework, key roles, the dual obligation model, Class A notification, device lifecycle, glossary |
| Pre-Market | Classification (A/B/C/D), device grouping, registration via SHARE, evaluation routes, overseas reference agencies, clinical evidence, special device types including SaMD |
| Post-Market | Adverse event reporting, FSCAs, post-market surveillance, change notifications, labelling and advertising, Free Sale Certificates |
| Dealer's Licence | Who needs a licence, manufacturer/importer/wholesaler distinctions, QMS and GDP requirements, applying via SHARE, audit process, maintaining and renewing |
| Legislation & Regulations | Health Products Act (Cap. 122D), HP(MD) Regulations 2010, related instruments, how to read Singapore legislation |
| International & ASEAN | Regulatory reliance, IMDRF, ASEAN AMDC, ASEAN CSDT, comparison of Singapore with TGA/FDA/CE/Health Canada |
| Guidance Documents | Full index of HSA guidance documents by topic and device class, forms, portals, fees and turnaround times |
| What's New | Recent regulatory changes, open consultations, upcoming changes, reforms tracker |
Where to start
If you are new to Singapore medical device regulation: → What is a Medical Device?
If you need to understand the registration vs licensing distinction: → The Dual Obligation Model
If you need to classify a device: → How Classification Works
If you are working out which registration route applies: → Evaluation Routes
If you need to apply for a dealer's licence: → Dealer's Licence — Overview
If you need to report an adverse event: → Adverse Event Reporting — What Must Be Reported
If a Field Safety Corrective Action may be required: → FSCA — When to Report
If you are an overseas manufacturer entering the Singapore market: → Singapore in the International Regulatory Landscape
Questions, corrections and discussions
RAPath SG is a community reference. If you find an error, have a regulatory question, or want to discuss a recent HSA change, use GitHub Discussions:
Regulatory affairs professionals who flag inaccuracies are the most valuable contributors to this project.
Disclaimer
Content on this site is written with AI assistance and is intended as a navigation aid only. Always verify against official HSA and Singapore Statutes Online sources before making regulatory decisions. This site is not affiliated with the Health Sciences Authority or the Singapore Government. Not legal or regulatory advice.